Determination of Blomia Tropicalis Allergen Extract in Prick Test Units
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-64
SponsorInmunotek S.L.
About this trial
The primary objective is to assess the concentration of Blomia tropicalis allergenic extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution, in order to be used as in-house reference preparation (IHRP).
Eligibility criteria
Qualifiers
Female or male aged 18 to 64 years, both included.
Subjects who have signed and dated the informed consent form.
Subjects must reside in a geographical area where allergic problems caused by Blomia tropicalis are relevant.
Positive medical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to Blomia tropicalis
Disqualifiers
Subjects outside the age range.
Subjects who have previously received immunotherapy within the last 5 years for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Blomia tropicalis extract.
Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in whom discontinuation of systemic antihistamine treatment is contraindicated.
Subjects who have previously exhibited a severe adverse reaction during diagnostic skin prick tests.
Trial design
Treatments tested in this trial
- Allergenic Extract
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov